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Introduction. Currently there are no industrial eukaryotic expression systems other than transient 
expression from plasmids or expression from genes integrated into host genome. Both approaches (use 
of eukaryotic plasmids or chromosomal integration) suffer from poor scalability and often from poor 
yields. Although, in laboratory settings, effective means for transducing of cultured cells to express 
foreign proteins and for high-level transient expression were developed based on viral genomes. We 
thought to develop a scalable and suitable for industrial application technology for the production of 
recombinant human erythropoietin (EPO) in mammalian cell cultures using an expression vector based 
on the genome of RNA virus. 
Materials and methods. We produced full-length cDNA copy of the genome of the Venezuelan 
equine encephalomyelitis virus (VEE). The copy of VEE genome was cloned into E.coli plasmid for the 
convenience of genetic engineering. Synthetic gene encoding the EPO was produced by the de novo 
synthesis from oligonucleotides. The expression cassette was produced for insertion of the EPO gene into 
the VEE genome. The genomic RNA of recombinant virus was produced and transfected into cultured 
mammalian cells. 
Results and discussion. The genome of VEE (strain TC-83) was produced by ligation of long PCR-
amplified cDNA fragments. The 5"- and 3"-ends ofthe VEE genome were assembled from oligonucleotides. 
The full-length copy of VEE genome (11473 bp) was cloned into plasmid pVEE/TC-83 under control of 
promoter of SP6 RNA polymerase. The expression cassette GFP-2A-EPO was designed. This expression 
cassette encodes a polyprotein consisting from sequences of green fluorescent protein (GFP), foot-and-
mouth disease protease 2A, and EPO. The GFP was included into the expression cassette with intention 
of convenient observation of the intracellular replication of the VEE RNA. The foot-and-mouth disease 
protease 2A is a short aminoacid sequence (17 aa) which presence leads to cotranslational cleavage of the 
polyprotein into the GFP-2A and EPO parts. The EPO is thought to be liberated from the polyprotein by 
action ofthe 2A protease. The expression cassette GFP-2A-EPO was cloned into the pVEE/TC-83, resulting 
in development of the construct pVEE/GFP-2A-EPO which encodes the autonomously replicating viral 
genome fragment capable of producing GFP and EPO during intracellular replication. Viral RNA (VEE/ 
GFP-2A-EPO RNA) was synthesized in vitro in a reaction catalyzed by the SP6 RNA polymerase and 
transfected into the cultured baby hamster kidney (BHK-21) cells. The transfection results indicate that 
the viral genome VEE/GFP-2A-EPO is viable and capable of production of heterologous proteins in the 
infected cells. 
Conclusions. Further development of this strategy will result in a callable expression system for 
production of the recombinant EPO and other proteins in mammalian and insect cells. 
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